DK1648505T3 - Quil A-fraktion med lav toksicitet og anvendelse deraf - Google Patents

Quil A-fraktion med lav toksicitet og anvendelse deraf

Info

Publication number
DK1648505T3
DK1648505T3 DK04749076T DK04749076T DK1648505T3 DK 1648505 T3 DK1648505 T3 DK 1648505T3 DK 04749076 T DK04749076 T DK 04749076T DK 04749076 T DK04749076 T DK 04749076T DK 1648505 T3 DK1648505 T3 DK 1648505T3
Authority
DK
Denmark
Prior art keywords
quil
fraction
adjuvant
lps
derivatives
Prior art date
Application number
DK04749076T
Other languages
English (en)
Inventor
Kefie Hu
Bror Morein
Bengtsson Karin Loevgren
Jill Ekstroem
Katarina Ranlund
Original Assignee
Isconova Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isconova Ab filed Critical Isconova Ab
Application granted granted Critical
Publication of DK1648505T3 publication Critical patent/DK1648505T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
DK04749076T 2003-07-07 2004-07-07 Quil A-fraktion med lav toksicitet og anvendelse deraf DK1648505T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301998A SE0301998D0 (sv) 2003-07-07 2003-07-07 Quil A fraction with low toxicity and use thereof
PCT/SE2004/001038 WO2005002620A1 (en) 2003-07-07 2004-07-07 Quil a fraction with low toxicity and use thereof

Publications (1)

Publication Number Publication Date
DK1648505T3 true DK1648505T3 (da) 2009-12-21

Family

ID=27731119

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04749076T DK1648505T3 (da) 2003-07-07 2004-07-07 Quil A-fraktion med lav toksicitet og anvendelse deraf

Country Status (15)

Country Link
US (8) US8821881B2 (da)
EP (1) EP1648505B1 (da)
JP (1) JP4731475B2 (da)
AT (1) ATE442164T1 (da)
AU (1) AU2004254152B2 (da)
BR (1) BRPI0412444B8 (da)
CA (1) CA2529363C (da)
DE (1) DE602004023089D1 (da)
DK (1) DK1648505T3 (da)
ES (1) ES2331952T3 (da)
NZ (1) NZ544299A (da)
PL (1) PL1648505T3 (da)
SE (1) SE0301998D0 (da)
WO (1) WO2005002620A1 (da)
ZA (1) ZA200600151B (da)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7049302B1 (en) * 1998-08-10 2006-05-23 Antigenics Inc. Compositions of CPG and saponin adjuvants and uses thereof
SE0202110D0 (sv) * 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) * 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
CA2592627C (en) 2005-01-20 2014-02-25 Isconova Ab Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
EP1764369A1 (de) * 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
EP2004226A1 (en) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Storage of influenza vaccines without refrigeration
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
EP1902727A1 (de) * 2006-09-22 2008-03-26 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
WO2008031878A1 (en) * 2006-09-15 2008-03-20 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH A composition for therapy and/or for prophylaxis of hbv-infections and hbv-mediated diseases
AU2007322424B2 (en) * 2006-11-20 2013-05-16 Duecom Use of lipid containing particles comprising quillaja saponins for the treatment of cancer
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
MX2010014026A (es) 2008-06-27 2011-02-15 Pfizer Composiciones adyuvantes novedosas.
AU2010269148A1 (en) * 2009-07-10 2012-01-19 Isconova Ab New composition
EP2618838A1 (en) 2010-09-20 2013-07-31 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
US10047116B2 (en) 2011-10-03 2018-08-14 Mx Adjuvac Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
CA2857087C (en) 2011-11-28 2021-05-25 Crucell Holland B.V. Influenza virus vaccines and uses thereof
JP5770952B2 (ja) 2012-03-12 2015-08-26 クルセル ホランド ベー ヴェー 改変末端を有する組換えアデノウイルスのバッチ
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
EA026504B1 (ru) 2012-03-22 2017-04-28 Круселл Холланд Б.В. Вакцина против rsv
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
JP6494527B2 (ja) 2013-02-07 2019-04-03 ザ チルドレンズ メディカル センター コーポレーション 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原
AP2015008702A0 (en) 2013-03-08 2015-09-30 Crucell Holland Bv Acellular pertussis vaccine
US9907846B2 (en) 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
JP6469081B2 (ja) 2013-04-25 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された可溶性融合前ｒｓｖｆポリペプチド
SG11201509663PA (en) 2013-05-30 2015-12-30 Crucell Holland Bv Influenza virus vaccines and uses thereof
MY171210A (en) 2013-06-17 2019-10-02 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f polypeptides
US10806779B2 (en) 2013-07-02 2020-10-20 Janssen Vaccines & Prevention B.V. Method for preparing virosomes
EP3017040B1 (en) 2013-07-02 2018-06-06 Janssen Vaccines & Prevention B.V. Method for preparing virosomes
KR101943171B1 (ko) 2013-09-19 2019-01-29 조에티스 서비시즈 엘엘씨 유성 아쥬반트
DE102014005771A1 (de) 2014-04-23 2015-10-29 Clariant International Ltd. Verwendung von wässrigen driftreduzierenden Zusammensetzungen
MY187261A (en) 2014-07-10 2021-09-16 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
HUE040440T2 (hu) 2014-11-04 2019-03-28 Janssen Vaccines & Prevention Bv Terápiás HPV16-oltóanyagok
DK3244920T5 (da) 2015-01-16 2024-10-07 Zoetis Services Llc Mund- og klovsyge-vaccine
WO2016166088A1 (en) 2015-04-14 2016-10-20 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
CN107847581B (zh) 2015-07-07 2022-03-22 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
ES2839880T3 (es) 2015-07-07 2021-07-06 Janssen Vaccines & Prevention Bv Vacuna contra el VRS
KR20180042295A (ko) 2015-08-20 2018-04-25 얀센 백신스 앤드 프리벤션 비.브이. 치료용 hpv18 백신
US10538557B2 (en) 2015-09-02 2020-01-21 Janssen Vaccines & Prevention B.V. Stabilized viral class I fusion proteins
EP4494650A3 (en) 2015-09-03 2025-03-26 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
EP3393512B1 (en) 2015-12-23 2025-11-19 Pfizer Inc. Rsv f protein mutants
KR102500970B1 (ko) 2016-04-05 2023-02-17 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
PH12022552125A1 (en) 2016-04-05 2023-04-12 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f proteins
EP3452087A1 (en) 2016-05-02 2019-03-13 Janssen Vaccines & Prevention B.V. Therapeutic hpv vaccine combinations
DE102016207877A1 (de) 2016-05-09 2017-11-09 Clariant International Ltd Stabilisatoren für Silikatfarben
CN109154000B (zh) 2016-05-12 2022-07-05 扬森疫苗与预防公司 有效和平衡的双向启动子
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
KR102307065B1 (ko) 2016-06-20 2021-09-30 얀센 백신스 앤드 프리벤션 비.브이. 강력하고 균형 잡힌 양방향성 프로모터
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
DE112017005577T5 (de) 2016-11-04 2019-08-29 Cabot Corporation Nanokomposite, enthaltend kristallinen Polyester und Organosiliciumdioxid
CN110268061B (zh) 2017-02-09 2024-07-16 扬森疫苗与预防公司 用于表达异源基因的有效的短启动子
US11229692B2 (en) 2017-05-17 2022-01-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
WO2019023196A1 (en) 2017-07-24 2019-01-31 Novavax, Inc. METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASE
WO2019053109A1 (en) 2017-09-15 2019-03-21 Janssen Vaccines & Prevention B.V. METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV
SMT202200354T1 (it) 2018-01-23 2022-09-14 Janssen Vaccines & Prevention Bv Vaccino per virus dell'influenza e suoi usi
EP3768308A4 (en) 2018-03-19 2022-01-26 Novavax, Inc. MULTIVALENT INFLUENZA NANOPARTICLE VACCINES
GB201807303D0 (en) 2018-05-03 2018-06-20 London School Of Hygeine & Tropical Medicine Glyconjugate vaccines
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
JP2022513025A (ja) 2018-11-13 2022-02-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化された融合前ｒｓｖ ｆタンパク質
BR112021020907A2 (pt) 2019-04-25 2022-04-19 Janssen Vaccines & Prevention Bv Antígenos de influenza recombinantes
US20220273787A1 (en) 2019-05-15 2022-09-01 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
US20220193219A1 (en) 2019-05-15 2022-06-23 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
JP2022547107A (ja) 2019-09-05 2022-11-10 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザウイルスワクチン及びその使用
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
TW202204380A (zh) 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗
WO2021229450A1 (en) 2020-05-11 2021-11-18 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
MX2022014162A (es) 2020-05-11 2023-02-23 Janssen Pharmaceuticals Inc Proteínas de fusión de la proteína de la espícula del coronavirus estabilizadas.
AU2021271300A1 (en) 2020-05-11 2023-02-02 Janssen Pharmaceuticals, Inc. RNA replicon encoding a stabilized corona virus spike protein
MX2023000024A (es) 2020-06-29 2023-04-12 Janssen Vaccines & Prevention Bv Combinación vacunal contra la infección por el virus respiratorio sincicial.
JP2023532369A (ja) 2020-07-06 2023-07-27 ヤンセン ファーマシューティカルズ，インコーポレーテッド 安定化されたコロナウイルススパイクタンパク質融合タンパク質
JP7822149B2 (ja) 2020-10-02 2026-03-02 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2022175477A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
KR20230165275A (ko) 2021-04-01 2023-12-05 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합 전 piv3 f 단백질
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023047349A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2023047348A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
EP4448802A1 (en) 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
JP2025511756A (ja) 2022-04-08 2025-04-16 フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー ワクチン及び関連する方法
WO2023217988A1 (en) 2022-05-12 2023-11-16 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2024017682A1 (en) 2022-07-18 2024-01-25 Janssen Vaccines & Prevention B.V. Rsv immunogens
JP2025525778A (ja) 2022-08-01 2025-08-07 フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー 免疫調節タンパク質及び関連方法
WO2024061759A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
WO2024061753A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized trimeric class i fusion proteins
WO2024061757A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
CN120344553A (zh) 2022-10-06 2025-07-18 Msd国际商务股份有限公司 稳定的融合前piv3 f蛋白
JP2025537776A (ja) 2022-11-14 2025-11-20 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザｂ型ウイルスワクチン及びその使用
WO2024151583A2 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
JP2026504862A (ja) 2023-01-18 2026-02-10 ファイザー・インク 呼吸器疾患に対するワクチン
WO2024167885A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods
KR20250152090A (ko) 2023-02-21 2025-10-22 엠에스디 인터내셔널 비즈니스 게엠베하 이종 삼량체화 도메인이 없는 안정화된 삼량체 rsv 융합 단백질
WO2024258829A1 (en) 2023-06-12 2024-12-19 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
TW202545974A (zh) 2024-01-26 2025-12-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 免疫受體抑制蛋白及相關方法
WO2025163460A2 (en) 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
WO2025240680A1 (en) 2024-05-16 2025-11-20 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025245111A1 (en) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Immunoreceptor targeting proteins and related methods
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
WO2026038177A1 (en) 2024-08-16 2026-02-19 Pfizer Inc. Immunogenic compositions and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5839376B2 (ja) * 1978-10-30 1983-08-30 富士通株式会社 イオン注入法
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
ES2039229T3 (es) 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
NL9002314A (nl) 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SE9600647D0 (sv) * 1996-02-21 1996-02-21 Bror Morein Ny användning
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
SE0202110D0 (sv) * 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof

Also Published As

Publication number Publication date
AU2004254152A1 (en) 2005-01-13
AU2004254152B2 (en) 2009-10-29
US20200345840A1 (en) 2020-11-05
US20060239963A1 (en) 2006-10-26
US20240024468A1 (en) 2024-01-25
ES2331952T3 (es) 2010-01-21
BRPI0412444B8 (pt) 2021-05-25
BRPI0412444B1 (pt) 2016-06-14
US20160184427A1 (en) 2016-06-30
CA2529363C (en) 2013-04-02
US20150320858A1 (en) 2015-11-12
ATE442164T1 (de) 2009-09-15
US20220241408A1 (en) 2022-08-04
EP1648505B1 (en) 2009-09-09
WO2005002620A1 (en) 2005-01-13
BRPI0412444A (pt) 2006-09-19
SE0301998D0 (sv) 2003-07-07
CA2529363A1 (en) 2005-01-13
PL1648505T3 (pl) 2010-02-26
JP4731475B2 (ja) 2011-07-27
US20140335049A1 (en) 2014-11-13
JP2007527386A (ja) 2007-09-27
ZA200600151B (en) 2007-01-31
US8821881B2 (en) 2014-09-02
US20180369368A1 (en) 2018-12-27
NZ544299A (en) 2009-03-31
US12171828B2 (en) 2024-12-24
EP1648505A1 (en) 2006-04-26
DE602004023089D1 (de) 2009-10-22

Similar Documents

Publication Publication Date Title
DK1648505T3 (da) Quil A-fraktion med lav toksicitet og anvendelse deraf
MX393384B (es) Adyuvantes sinteticos de glucopiranosil-lipido.
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
BRPI0619795B8 (pt) composição imunogênica, composição adjuvante, e, uso de uma composição imunogênica e um adjuvante
MY137619A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2007109812A3 (en) Immunopotentiating compounds
BRPI0415699A (pt) uso de oligossacarìdeo ácido e de oligossacarìdeo neutro, e, composições alimentìcia e lìquida
WO2006086449A3 (en) Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
NO20064781L (no) Fremgangsmater og adjuvanser for a forbedre immunresponser mot vaksiner og fremgangsmater for anvendelse
MX2007003078A (es) Compuestos de imidazoquinolina.
BR122018075729B8 (pt) flavivírus na preparação de uma composição de vacina
WO2009095226A3 (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
TW200643028A (en) Vaccine
MX2007014082A (es) Pirido[2,3-d]pirimidinas utiles como inhibidores del virus de la hepatitis c (hcv), y metodos para la preparacion de las mismas.
AR044696A1 (es) Composicion de vacunas
CR8862A (es) Derivados de polisacaridos y sus usos en la induccion de una respuesta inmune
WO2016179034A3 (en) Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs
BRPI0511026A (pt) uso de um los neisserial, e, composição
MXPA05006269A (es) Uso de un extracto de granos de cafe descafeinado en la preparacion de una composicion destinada a estimular la funcion sebacea de la piel mediante administracion oral.
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
AU5162201A (en) Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
MX2009011384A (es) Combinaciones adyuvantes que comprenden un activador de nkt, un agonista de cd40 y opcionalmente un antígeno y uso de las mismas para inducir un aumento sinergístico en la inmunidad celular.
BRPI0513288A (pt) uso de alcanóis fosfatados como dispersantes, emulsificantes, hodrótropos, agentes umectantes e agentes de compatabilidade em composições agriculturais
EP1905449A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
SG147465A1 (en) Vaccine